PQA 08 - PQA 08 Genitourinary Cancer, Patient Safety, and Nursing/Supportive Care Poster Q&A

Tuesday, October 1, 2024

2:30 PM – 3:45 PM ET

Location: Hall C

This event is in-person only and won't be livestreamed or available onDemand.

Presentations:

2:30 PM – 3:45 PM ET

Assessment of Pattern of Requirement of General Anesthesia for Pediatric Patients Undergoing Radiotherapy
Presenter: Aashita Aashita, MD – NCI AIIMS
2:30 PM – 3:45 PM ET

Early PSA Kinetics in Patients Treated with Prostate SBRT with Intra-Prostatic Boost
Presenter: Nima Aghdam, MD, MS – Beth Israel Deaconess Medical Center
2:30 PM – 3:45 PM ET

National Value-Based Care Competition - A Six Sigma Training Program
Presenter: James Alin, BS – Medical College of Georgia
2:30 PM – 3:45 PM ET

Ablative Radiotherapy for Unfavorable Prostate Tumors (ABRUPT): Analysis of Toxicity and Quality of Life from a Prospective Study
Presenter: Stefano Arcangeli, MD – University of Milan Bicocca
2:30 PM – 3:45 PM ET

Utilizing of a Dedicated Radiation Oncology Documentation Software Designed with Physician Input and Note Completion Times
Presenter: Joshua Asper, PA-C – Mays Cancer Center, UT Health San Antonio, MD Anderson Cancer Center
2:30 PM – 3:45 PM ET

Managing for Daily Improvement: A System for Real-Time Quality Improvement and Patient Safety
Presenter: Margaret Barker, MS – MemorialCare Long Beach Medical Center
2:30 PM – 3:45 PM ET

Node Positive Prostate Cancer Treated with Brachytherapy Boost
Presenter: Rahul Barve, MD – Memorial Sloan Kettering Cancer Center
2:30 PM – 3:45 PM ET

Patient Reported Quality of Life (QOL) Outcomes for Intermediate-High Risk-Very High Risk Prostate Cancers Treated By SBRT and Androgen Deprivation Therapy (ADT)
Presenter: Trinanjan Basu, MD – HCG Cancer Center, Mumbai
2:30 PM – 3:45 PM ET

Association of Tumor Volume and Radiographic T-Stage for Patients with Localized Prostate Cancer Treated with Radiation or Radical Prostatectomy
Presenter: Martin King, MD, PhD – Brigham and Womens Hospital
2:30 PM – 3:45 PM ET

Daily Adaptive Post-Prostatectomy Radiation Therapy (DAPPER): Initial Treatment Planning and Delivery Outcomes Using CT-Based Online Adaptive Radiation Therapy
Presenter: Alexandra Bennett, MD – Mayo Clinic College of Medicine and Science Rochester
2:30 PM – 3:45 PM ET

Effectiveness of an Iodinated Perirectal Hydrogel Spacer for Prostate Cancer Treated with Stereotactic Body Radiotherapy (SBRT): A Prospective, Multi-Center, Randomized Trial ("SABRE")
Presenter: Pierre Blanchard, MD, PhD – Gustave Roussy Cancer Center
2:30 PM – 3:45 PM ET

Development of a Consensus Checklist for Systematic Radiation Treatment Plan Review
Presenter: Graham Boyd, MD – Dana-Farber/Brigham and Women's Cancer Center
2:30 PM – 3:45 PM ET

MRI-Guided Adaptive SBRT for Kidney and Adrenal Gland Tumors: An Analysis of the Intra-Fractional Tumor Motion and Inter-Fractional Dosimetric Impact
Presenter: Lingling Cai, MB – Sun Yat-Sen University Cancer Center
2:30 PM – 3:45 PM ET

3D-Printed Seed Placement Template for ¹²⁵I Seed Plaque Assembly with Custom Eye Plaques
Presenter: Kaitlyn Calabresi, BS – Louisiana State University Health Sciences Center
2:30 PM – 3:45 PM ET

Geographical Comparison of Medicare & Medicaid Services (CMS) Standard Charges for Complex Proton Therapy
Presenter: Kasey Cargill, PhD – University of Pittsburgh School of Medicine
2:30 PM – 3:45 PM ET

Severe Genitourinary Events Following Definitive Radiation Therapy for Patients with Locally Advanced and Metastatic Bladder Cancer: A Single Institution Experience
Presenter: Patrick Carriere, MD, PhD – MD Anderson Cancer Center
2:30 PM – 3:45 PM ET

An LLM-Based Framework for Zero-Shot De-Identifying Flexible Text Data in Protected Health Information Enabling Potential Risk-Informed Patient Safety
Presenter: Chih-Wei Chang, PhD – Emory University
2:30 PM – 3:45 PM ET

Stereotactic Body Radiotherapy for Prostate Cancer with Magnetic Resonance Imaging or Computed Tomography Guidance
Presenter: Enoch Chang, MD – MD Anderson Cancer Center
2:30 PM – 3:45 PM ET

Clinical Efficacy and Adverse Effects of Adjuvant Radiotherapy Following Surgery in High-Risk Renal Cell Carcinoma(RCC) Patients - A Single Center Experience
Presenter: Jiayan Chen, MD – Peking University First Hospital
2:30 PM – 3:45 PM ET

Racial Variation in the Advanced Prostate Cancer Genome
Presenter: William Chen, MD – UCSF
2:30 PM – 3:45 PM ET

Care Coordination for Patients with Cardiac Implantable Electronic Devices Scheduled to Receive Radiation
Presenter: Walter Chin, MS, BSN – Emory Clinic
2:30 PM – 3:45 PM ET

Treatment Terminations during Radiation Therapy: A Decade of Genitourinary Terminations
Presenter: Bhargava Chitti, MD – Northwell Health Center for Advanced Medicine
2:30 PM – 3:45 PM ET

Morphological Variation in Rectal Hydrogel Spacer One Month after Insertion during Low Dose Rate Brachytherapy for Prostate Adenocarcinoma
Presenter: Hyeok Choi, MD – Yonsei Cancer Center
2:30 PM – 3:45 PM ET

Dosimetric Comparison of Margin-Reduced CT-Guided with MRI-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer
Presenter: Patrick Courtney, MD, MAS – UCLA David Geffen School of Medicine/UCLA Medical Center
2:30 PM – 3:45 PM ET

Clinical and Dosimetric Outcomes of Patients Who Received Daily-Adaptive Post-Prostatectomy Salvage Radiation
Presenter: Michael Cummings, MD – University of Rochester Medical Center
2:30 PM – 3:45 PM ET

EQD2 Constraints for Organs at Risk in Re-Irradiation Planning for Thoracic and Head and Neck Cancers
Presenter: Samira Dabaghmanesh, PhD – Medical College of Wisconsin
2:30 PM – 3:45 PM ET

Evaluation of Clinical and Educational Impact of Head and Neck-Specific Chart Rounds in a High-Volume Multi-Center Integrated Health Care System
Presenter: Fara Dayani, MD, MS – Kaiser Permanente Los Angeles Medical Center
2:30 PM – 3:45 PM ET

Stereotactic Ablative Radiotherapy for Renal Cell Carcinomas - An Experience from a Single Center
Presenter: Tomás De Souza, MD – McGill University Health Centre
2:30 PM – 3:45 PM ET

Hypofractionated Intensity Modulated Radiation Therapy and Weekly Gemcitabine for Muscle Invasive Bladder Cancer. Long-Term Results
Presenter: Tomás De Souza, MD – McGill University Health Centre
2:30 PM – 3:45 PM ET

Impact of a Nurse Practitioner-Led Follow-Up Clinic within a Rapid-Access Palliative Radiotherapy Program for Patients with Metastatic Cancer
Presenter: Katherine Del poso-Lee, MSN, NP-PHC – Princess Margaret Cancer Centre
2:30 PM – 3:45 PM ET

Exploring the Role of Angiotensin Converting Enzyme Inhibitors in Genito-Urinary Toxicity Following Curative Radiotherapy for Bladder Cancer
Presenter: Ayo Olowofela, MD, MS – Medical College of Wisconsin
2:30 PM – 3:45 PM ET

International Harmonization of Technical Approaches to Kidney SABR - An International Radiosurgery Consortium of the Kidney (IROCK) Contouring Project
Presenter: Aneesh Dhar, MD, MS, FRCPC – Memorial Sloan Kettering Cancer Center
2:30 PM – 3:45 PM ET

Differential Use of Radiotherapy Fractionation Regimens for Muscle-Invasive Bladder Cancer
Presenter: Marshall Diven, MD – NYP/BMH
2:30 PM – 3:45 PM ET

Care Alerts for Readiness Excellence (CARE): Initiative to Reduce Symptom-Related Treatment Delays
Presenter: Victoria Doss, MD – Johns Hopkins Medicine
2:30 PM – 3:45 PM ET

Risk of Death in Octogenarians with Intermediate Risk Prostate Cancer Who Are Treated with Radiation Therapy (RT) Plus Androgen Deprivation Therapy (ADT) Versus Radiation Alone, an NCDB Analysis
Presenter: Timothy Dougherty, MD – Allegheny Health Network
2:30 PM – 3:45 PM ET

Apparent Diffusion Coefficient as an Early Prognostic Factor of Response to Treatment with Androgen Deprivation Therapy and Radiotherapy in Patients with Prostate Cancer
Presenter: Ana Aurora Diaz-Gavela, MD – Hospital Universitario Quiron Madrid
2:30 PM – 3:45 PM ET

Evaluating Guideline-Concordant Androgen Deprivation for High-Risk Prostate Cancer in a Statewide Quality Consortium
Presenter: Michael Dykstra, MD – University of Michigan
2:30 PM – 3:45 PM ET

Prostate Cancer in Southeast Asia: An Analysis of 2022 Incidence and Mortality Data
Presenter: Michelle Ann Eala, MD – UCLA David Geffen School of Medicine/UCLA Medical Center
2:30 PM – 3:45 PM ET

The State of Peer Review Practice in Community Radiation Oncology: Results of a National Survey of NCORP Network Sites
Presenter: Michael Farris, MD – Wake Forest University Medical Center
2:30 PM – 3:45 PM ET

Triage Schema for O-Ring vs. C-Arm Gantry Machine Load Balancing
Presenter: Seth Fehrs, MS – Emory University
2:30 PM – 3:45 PM ET

Real-World Medical Device Reports of PEG Hydrogel Spacers: Analysis of the FDA Manufacturer and User Facility Device Experience (MAUDE) Database
Presenter: Michael Folkert, MD, PhD – University of Washington-Fred Hutchinson Cancer Center
2:30 PM – 3:45 PM ET

Early Results from a Prospective Trial Testing Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR(NCT05455736)
Presenter: Giulio Francolini, MD – Azienda Ospedaliera Universitaria Careggi
2:30 PM – 3:45 PM ET

Matching Strategy on the Use of Image-Guided Hypo-Fractionated Radiotherapy for Localized Prostate Cancer
Presenter: Yan Gao, MS – Peking University First Hospital
2:30 PM – 3:45 PM ET

Prostate Moderate Hypo-Fractionated Radiotherapy: Urethral and Bladder Dose-Effect Relations in Genitourinary Toxicity and Dosimetric Advantages of Urinary Protection Technique
Presenter: Yan Gao, MS – Peking University First Hospital
2:30 PM – 3:45 PM ET

Factors Associated with Successful CT Simulation in Prostate Cancer Radiotherapy
Presenter: Karishma George, MD, MBBS, DNB – Tom Baker Cancer Centre / University of Calgary
2:30 PM – 3:45 PM ET

Disease Site Specific Peer Review Highlights the Need for Prospective Contour Review for Head and Neck Treatment Planning
Presenter: Beth Ghavidel, MS – Winship at Emory University Hospital Midtown
2:30 PM – 3:45 PM ET

Enhancing Workflow Efficiency for Managing Patients with Cardiac Implantable Electronic Devices in Radiation Oncology: A Lean Approach
Presenter: Beth Ghavidel, MS – Winship at Emory University Hospital Midtown
2:30 PM – 3:45 PM ET

Pattern of Failure Following Salvage Radiation Therapy after Prostatectomy
Presenter: Lucia Goanta, MD – Regina Elena National Cancer Institute
2:30 PM – 3:45 PM ET

International Prostate Symptom Score Outcomes of Five Different Treatment Paradigms for Localized Prostate Cancer: A Single-Institution Experience
Presenter: Nicholas Gravbrot, MD – University of Utah Huntsman Cancer Institute
2:30 PM – 3:45 PM ET

The Effect of Age on Clinicopathological Features and Treatment Outcomes of Patients Receiving Definitive Radiotherapy for Localized Prostate Cancer
Presenter: Ozan Cem Guler, MD – Baskent University
2:30 PM – 3:45 PM ET

Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Radiation Therapy in Two Fractions for Locally Recurrent Prostate Cancer after Definitive Radiation Therapy
Presenter: Liat Hammer, MD, PhD – Sheba Medical Center
2:30 PM – 3:45 PM ET

Effect of Ethnic Concordance in Post-Treatment Follow-Up and Surveillance of Korean American Breast Cancer Patients Treated with Adjuvant Radiotherapy
Presenter: Hye Ri Han, MD, MS – University of Southern California/Los Angeles General Medical Center
2:30 PM – 3:45 PM ET

Clinical Workflow Evaluation of High-Performance Imaging on a C-Arm Linear Accelerator
Presenter: Robyn Handschuh, MS, DABR – The Ohio State University James Cancer Hospital
2:30 PM – 3:45 PM ET

Stereotactic Body Radiotherapy (SBRT) as Definitive Management for Renal Cell Carcinoma with and without Real-Time MRI Guidance
Presenter: Colin Harari, MD – University of Wisconsin Carbone Cancer Center
2:30 PM – 3:45 PM ET

Toxicity Comparison of Whole Pelvic vs. Prostate Only Proton Therapy - Results from the Proton Collaborative Group PCG 001-09
Presenter: Ananya Raghavan, BS – New York Proton Center
2:30 PM – 3:45 PM ET

A Phase Il Clinical Study of Axitinib and Toripalimab Combined with Stereotactic Radiation (SBRT) for Metastatic Renal Cell Carcinoma (mRCC) after Oligoprogression from First-Line Anti-Angiogenic Ther
Presenter: Lingling Cai, MB – Sun Yat-Sen University Cancer Center
2:30 PM – 3:45 PM ET

A Phase Il Clinical Study of Axitinib and Toripalimab Combined with Stereotactic Radiation (SBRT) for Metastatic Renal Cell Carcinoma (mRCC) after Oligoprogression from First-Line Anti-Angiogenic Ther
Presenter: Liru He, PhD – Sun Yat-Sen University Cancer Center
2:30 PM – 3:45 PM ET

Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer and Its Reversal
Presenter: Anne Hong, MD – Austin Health
2:30 PM – 3:45 PM ET

The Performance of Multiparametric MRI in Identification of Intraprostatic Tumor Deposits after Local Prostate Radiation Therapy
Presenter: R. Hsi, MD – University of Washington-Fred Hutchinson Cancer Center
2:30 PM – 3:45 PM ET

Mid-Term Analysis of the Combination Therapy of Axitinib, Toripalimab, and Stereotactic Ablative Body Radiotherapy (SABR) in the Treatment of Recurrent Metastatic Renal Cell Carcinoma
Presenter: Ke Hu, MD – Peking University First Hospital
2:30 PM – 3:45 PM ET

Outcomes of Primary Tumor Stereotactic Ablative Body Radiotherapy for Localized and Metastatic Renal Cell Carcinoma
Presenter: Daniel Huang, MD – University of Chicago
2:30 PM – 3:45 PM ET

Analysis of High-Volume Biopsy Core Involvement and Failure after SBRT Monotherapy for Intermediate Risk Prostate Cancer
Presenter: Vianca Santos, MPH – NYU Langone Health - Long Island
2:30 PM – 3:45 PM ET

Food Insecurity and Sociodemographic Influences on PSA Screening
Presenter: Vianca Santos, MPH – NYU Langone Health - Long Island
2:30 PM – 3:45 PM ET

Personalized Deep Learning Model for Target Volume Based on CBCT for Prostate Adaptive SBRT Patients
Presenter: Jin Sung Kim, PhD
2:30 PM – 3:45 PM ET

A Feasibility Study Assessed the Predictive Ability of MRI Delta-Radiomics for GU Toxicity and IPSS Changes in PCa Hypofractionated RT
Presenter: Haruo Inokuchi, MD, PhD – Osaka Metropolitan University Graduate School of Medicine
2:30 PM – 3:45 PM ET

Long-Term Outcomes of Image-Guided Proton Therapy with Gold Fiducial Marker for Localized Prostate Cancer
Presenter: Hiromitsu Iwata, MD, PhD – Nagoya City University West Medical Center
2:30 PM – 3:45 PM ET

Assessment of OpenAI-Based Chatbots Performance in Extracting Patient Consultation Information
Presenter: Julian Jeberaeel, DO – Detroit Medical Center/Wayne State University
2:30 PM – 3:45 PM ET

Radiation Therapy for Prostate Cancer: Baseline Platelet Count and Anti-Platelet and Anticoagulant Use Are Associated with Disease Outcomes in a Cohort of 1000 Men
Presenter: Matthew Ji, BS – University of Chicago
2:30 PM – 3:45 PM ET

Radiation Therapy for Prostate Cancer: Baseline Platelet Count and Anti-Platelet and Anticoagulant Use Are Associated with Disease Outcomes in a Cohort of 1000 Men
Presenter: Stanley Liauw, MD, FASTRO – University of Chicago
2:30 PM – 3:45 PM ET

Challenges in Developing an AI-Based Analysis System for Incident Learning
Presenter: Abbas Jinia, PhD – Memorial Sloan Kettering Cancer Center
2:30 PM – 3:45 PM ET

Artificial Intelligence Model Using PSMA PET Imaging of Primary Prostate Cancer for Analyzing Metastases and Post-Treatment Progression
Presenter: Jesus Juarez Casillas, MD, MS – UCLA
2:30 PM – 3:45 PM ET

Beating the Clock: An Audit of Time Taken to Deliver Swallowing Sparing IMRT for Head and Neck Carcinoma
Presenter: Yousra Izzuddeen KN, MD, MBBS, DNB – All India Institute of Medical Sciences
2:30 PM – 3:45 PM ET

Demographic differences between consenting versus non-consenting participants for biospecimen collection on NRG prostate cancer trials
Presenter: Sophia Kamran, MD – Massachusetts General Hospital
2:30 PM – 3:45 PM ET

Patterns of Leukopenia in Men with Prostate Cancer Receiving Definitive Pelvic Irradiation
Presenter: Ari Kassardjian, MD – City of Hope Comprehensive Cancer Center
2:30 PM – 3:45 PM ET

A Prospective Study of Stereotactic Body Radiotherapy in Oligometastatic Renal Cell Carcinoma
Presenter: Rohan Katipally, MD – University of Chicago Medical Center
2:30 PM – 3:45 PM ET

Intermediate Term Urinary Outcomes Following Prostate Radiation Therapy after Neoadjuvant Prostate Artery Embolization
Presenter: Vaseem Khatri, MD – Moffitt Cancer Center
2:30 PM – 3:45 PM ET

Psmaddition: Phase 3 Trial of [¹⁷⁷lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. Soc Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Presenter: Hyun Kim, MD – Washington University School of Medicine in St. Louis
2:30 PM – 3:45 PM ET

Context-Dependent Impact of Tumor-Infiltrating B Cells in High-Risk Prostate Cancer and Head and Neck Cancer
Presenter: Sangwoo Kim, MD – University of California, San Diego
2:30 PM – 3:45 PM ET

Inter- and Intra-Observer Variability in Catheter Localization in High-Dose-Rate Brachytherapy for Prostate Cancer with Stepping Transverse and Twister Sagittal Volume Scanning
Presenter: Soo Kyoung Kim, MD – UC Davis Cancer Center
2:30 PM – 3:45 PM ET

Acute Toxicity and Quality of Life in Postoperative Prostate Cancer Patients Treated with Ultra-Hypofractionated Pelvic Radiation Therapy
Presenter: Isidora King, MD – Clinica IRAM
2:30 PM – 3:45 PM ET

Oncologic Outcomes of Upfront Radiation Therapy vs. Surgery, while Accounting for Intraprostatic Tumor Volume
Presenter: Martin King, MD, PhD – Brigham and Womens Hospital
2:30 PM – 3:45 PM ET

¹⁸F-Flotufolastat Detection Rates in the Pelvis Region for Patients with Prostate Cancer Recurrence after Radical Prostatectomy and PSA Levels <1 ng/mL: Data from the Phase 3 SPOTLIGHT S
Presenter: Bridget Koontz, MD, FASTRO – AdventHealth Cancer Institute
2:30 PM – 3:45 PM ET

Association of MRI Capsular Involvement and Extraprostatic Extension on Metastasis Free and Overall Survival in Localized Prostate Cancer Treated with Radiation
Presenter: Abhishek Kumar, MD, MAS – Duke Cancer Institute
2:30 PM – 3:45 PM ET

Radiation Induced Lymphopenia Depends on Lymph Node Irradiation in Prostate Cancer Radiotherapy
Presenter: Lukasz Kuncman, MD, PhD – Fundacja im Jakuba Hrabiego Potockiego
2:30 PM – 3:45 PM ET

Efficacy of Oligometastasis Directed Stereotactic Body Radiation Therapy in De Novo Oligometastatic Prostate Cancer
Presenter: Dominic LaBella, MD – Thomas Jefferson University
2:30 PM – 3:45 PM ET

Efficacy of Oligorecurrence Directed Stereotactic Body Radiation Therapy in Oligorecurrent Prostate Cancer
Presenter: Dominic LaBella, MD – Thomas Jefferson University
2:30 PM – 3:45 PM ET

A Secondary Analysis of Radiotherapy Oncology Group (RTOG/NRG) Trials 9202, 9413, and 9910: Unknown Causes of Death and Their Impact on Prostate Cancer Specific Mortality Estimates
Presenter: Joan Lee, MD – University Hospitals Cleveland Medical Center
2:30 PM – 3:45 PM ET

Feasibility of PSMA PET-Assisted MR-Guided Radiotherapy for Prostate Cancer Patients Treated with Curative Aim
Presenter: Joon-gyo Lee, MD – Gachon University Gil Medical Center
2:30 PM – 3:45 PM ET

Prognostic Value of Central Gland Volume on MRI for Biochemical Recurrence after Prostate Cancer Radiotherapy
Presenter: Joseph Lee, MD, PhD – Corewell Health William Beaumont University Hospital
2:30 PM – 3:45 PM ET

Decoding Cancer Radiotherapy Discontinuation: A Comprehensive Analysis
Presenter: Huei Fang Yang, BS, RN – Chung Shan Medical University Hospital
2:30 PM – 3:45 PM ET

Apparent Diffusion Coefficient Tumor Volume is the Most Prognostic Radiomic Feature in Localized Prostate Cancer
Presenter: Jonathan Leeman, MD – Brigham and Women's Hospital/Dana-Farber
2:30 PM – 3:45 PM ET

The Effectiveness of Radiotherapy for Upper Tract Urothelial Carcinoma (UTUC) with Lymph Node Metastasis and Optimal Target Delineation for Clinical Target Volume
Presenter: Xiaoying Li, MD – Peking University First Hospital
2:30 PM – 3:45 PM ET

Impact of Hyaluronic Acid (HA) Rectal Spacer Quality Score (SQS) and Fischer-Valuck (FV) Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal (GI) Toxicity Outcomes - An Austr
Presenter: Yuan-Hong Lin, MD – Alfred Health
2:30 PM – 3:45 PM ET

Rectal Spacer Impact on MRI-Directed SBRT Prostate Microboost in Concert with Pelvic Nodal Irradiation
Presenter: Jonathan Lischalk, MD – New York University Perlmutter Cancer Center
2:30 PM – 3:45 PM ET

Exploring Gene Expression and Pathway Analysis in Localized Prostate Cancer: Insights from a Retrospective Cohort Study with a Focus on Hypoxia and Angiogenic Biomarkers Post-EBRT and HDR-BTb
Presenter: Taha Lodhi, MB, ChB – The Christie NHS Foundation Trust
2:30 PM – 3:45 PM ET

A Randomized Controlled Study of a New Model of Symptom Management Based on PRO in Patients with Head and Neck Tumors Receiving Radiotherapy
Presenter: Xiaoli Long
2:30 PM – 3:45 PM ET

A Prospective Cohort Study Assessing Patient Reported Outcomes after Post-Prostatectomy Radiation Therapy: Longer-Term Follow-Up through 5 Years
Presenter: Connor Lynch, MD – University of Chicago
2:30 PM – 3:45 PM ET

Impact of Posterior PTV Margin on the Treatment Efficiency and Adverse Effects of Radical Radiotherapy for Prostate Cancer Patients
Presenter: Lin Ma, MD – Peking University First Hospital
2:30 PM – 3:45 PM ET

A Prospective Cohort Study Evaluating the Efficacy and Safety of Adjuvant Chemotherapy in High-Risk Non-Metastatic Prostate Cancer Patients with High Gleason Scores
Presenter: Ming-Wei Ma, MD – Peking University First Hospital
2:30 PM – 3:45 PM ET

Patterns of Care and Associated Socioeconomic Determinants of Health in the Definitive Treatment of Localized Muscle-Invasive Bladder Cancer Patients
Presenter: Megan Mai, MPH – Texas Tech University Health Science Center
2:30 PM – 3:45 PM ET

Adaptive-Driven CT Simulation Free SBRT Workflow Validation and Initial Experience
Presenter: Victor Malkov, PhD, MCCPM – Mayo Clinic Rochester
2:30 PM – 3:45 PM ET

Estimating Life Expectancy prior to Curative Intent Prostate Radiation Therapy in Underserved Patient Populations
Presenter: Swati Mamidanna, MD – Rutgers Cancer Institute of New Jersey
2:30 PM – 3:45 PM ET

Evaluation of an Artificial Intelligence-Based Software for Adaptative Radiotherapy in Head and Neck Cancer Treatments
Presenter: Pauline Maury, PhD – Institut Gustave Roussy
2:30 PM – 3:45 PM ET

Peer Review as a Means of Improvement and Harmonization of Treatment Plans Among a Multinational Radiation Oncology Team
Presenter: Basma Mbarek, MD – far east medical
2:30 PM – 3:45 PM ET

Bladder Neck Dosimetry and Interfractional Variation in Proton Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Presenter: Hamilton McGinnis, MD – Emory University School of Medicine
2:30 PM – 3:45 PM ET

Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: A Report on Feasibility, Safety and Toxicity
Presenter: LaToya McLean, MD, MS, BS – Thomas Jefferson University
2:30 PM – 3:45 PM ET

Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Metastatic Renal Cell Carcinoma
Presenter: Elie Mehanna, MD – Harvard Radiation Oncology Program
2:30 PM – 3:45 PM ET

Reducing Patient Safety Risk with the Implementation of Intradepartmental Survey Program across a Multi-Site Large Teaching Institution
Presenter: Timothy Meier, RT, (R)(T) – Cleveland Clinic
2:30 PM – 3:45 PM ET

Radiotherapy is a Treatment Option for Cancer in the Very Old (80+): A Single Institution Experience
Presenter: Oliver Micke, MD – Franzikus Hospital Bielefeld
2:30 PM – 3:45 PM ET

Uptake and Positivity Rates of PSMA PET Staging for Newly Diagnosed Prostate Cancer in a National Healthcare System
Presenter: Sean Miller, MD – University of Michigan
2:30 PM – 3:45 PM ET

Radiotherapy Treatment with Radical Doses in De Novo Low Burden Metastatic Prostate Cancer: Early Outcomes Report.
Presenter: Benazir mir Khan, MD
2:30 PM – 3:45 PM ET

Respecting Patients Privacy Rights and Medical Data Safety at a Radiation Oncology Department during Remote Consultations and Surveillance
Presenter: Miroslawa Mocydlarz-Adamcewicz, PhD – Wielkopolskie Centrum Onkologii
2:30 PM – 3:45 PM ET

Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone
Presenter: Shalini Moningi, MD – Brigham and Women's Hospital/Dana-Farber
2:30 PM – 3:45 PM ET

A Randomized Phase II Trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) Brachytherapy as Monotherapy in Localized Prostate Cancer: Analysis of Initial Arms of Canadian Cancer Trials Group PR19 (NC
Presenter: Gerard Morton, MD – Sunnybrook Health Sciences Centre
2:30 PM – 3:45 PM ET

Correlation of Circulating Tumor DNA (ctDNA) Dynamics with Clinical Response in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Trimodality Therapy (TMT)
Presenter: Kent Mouw, MD, PhD – Dana-Farber/Brigham and Women's Cancer Center
2:30 PM – 3:45 PM ET

Customized Electronic Quality Checklists to Reduce Errors and Improve Radiotherapy Workflow
Presenter: Hussam Hijazi, MD, MB, BS, MBBS – King Abdulaziz University
2:30 PM – 3:45 PM ET

Comparison of Local Medicare Guidance and Medicare Advantage Plans for Stereotactic Radiosurgery for Brain Metastases
Presenter: Trey Mullikin, MD – Duke Cancer Institute
2:30 PM – 3:45 PM ET

Biochemical Recurrence is Not a Surrogate for Overall Survival in Localized Prostate Cancer: Data from 2 Phase III Trials
Presenter: Abdenour Nabid, MD – CHUS
2:30 PM – 3:45 PM ET

Quality of Life and Weight Variation during Androgen Deprivation Therapy in Patients with High-Risk Prostate Cancer: Long-Term Data from a Phase III Trial
Presenter: Abdenour Nabid, MD – CHUS
2:30 PM – 3:45 PM ET

Phase 2 Prospective Trial of Re-Treatment with ¹⁷⁷lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer (RE-LuPSMA): Study Protocol
Presenter: John Nikitas, MD – UCLA Radiation Oncology
2:30 PM – 3:45 PM ET

Treatment Terminations in Gynecological Malignancies
Presenter: Jason Nosrati, MD – Montefiore Einstein Cancer Center
2:30 PM – 3:45 PM ET

Comparison of Decipher vs. Oncotype (GPS) Genomic Profiling Scores in NCCN Intermediate Risk Prostate Cancer Patients
Presenter: Edward Obedian, MD – The Cancer Institute at St. Francis Hospital
2:30 PM – 3:45 PM ET

The Safety and Efficacy of Lutetium-177-PSMA-617 Therapy for Metastatic CRPC in a Real World Community Cancer Center
Presenter: Edward Obedian, MD – The Cancer Institute at St. Francis Hospital
2:30 PM – 3:45 PM ET

Investigating the Machine Learning-Derived Nomogram Models and Biomarkers for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer - Preliminary Results
Presenter: Oluwaseyi Oderinde, PhD – Purdue University
2:30 PM – 3:45 PM ET

Stereotactic Body Radiotherapy with Hydrogel Spacer for Prostate Cancer: 5-Year Follow-Up Results of a Phase 2 Trial
Presenter: Mami Ogita, MD, PhD – University of Tokyo Hospital
2:30 PM – 3:45 PM ET

Treatment Outcomes of External Beam Radiotherapy with or without Focal Boost to Intraprostatic Lesions in Patients with Localized Prostate Cancer
Presenter: Huseyin Cem Onal, MD – Baskent University Faculty of Medicine
2:30 PM – 3:45 PM ET

Impact of Definitive Radiotherapy on Metabolic Response Measured with ⁶⁸Ga-PSMA-PET/CT in Patients with Intermediate-Risk Prostate Cancer
Presenter: Huseyin Cem Onal, MD – Baskent University Faculty of Medicine
2:30 PM – 3:45 PM ET

Study on the Focal Boost to the Dominant Intraprostatic Lesions Using Proton Therapy in High-Risk Prostate Cancer Patients with Pelvic Lymph Node Irradiation: Assessing Toxicity Using the Accumulated
Presenter: Ashley Ong, PhD, CMD – National Cancer Centre Singapore
2:30 PM – 3:45 PM ET

Financial Difficulties and Long-Term Oncological Outcomes Following Prostate Radiotherapy and Androgen Deprivation Therapy - Post-Hoc Analyses of TROG0304/ RADAR Trial
Presenter: Wee Loon Ong, MBBS – Alfred Health Radiation Oncology
2:30 PM – 3:45 PM ET

Preoperative Intraprostatic Tumor Volume Is Prognostic for Metastasis after Early Salvage Post-Prostatectomy Radiation Therapy
Presenter: James Parisi, BS – Brigham and Womens Hopsital
2:30 PM – 3:45 PM ET

Brachytherapy Deserts in Texas: Assessment of Geographic Availability of Brachytherapy Centers
Presenter: Mayank Patel, MD, MBA – University of Miami
2:30 PM – 3:45 PM ET

Failure Patterns of Bladder Only Hypofractionated Radiation with Gemcitabine in Muscle Invasive Bladder Cancer (MIBC)
Presenter: Abigail Pepin, MD – University of Pennsylvania Health System
2:30 PM – 3:45 PM ET

Prospective Analysis on Tumor Control, Survival, Toxicity and Quality of Life Outcomes of an HDR-Brachytherapy Boost for Prostate Cancer
Presenter: Max Peters, RT – Radiotherapiegroep Arnhem
2:30 PM – 3:45 PM ET

Ultra-Short-Course Hormone Therapy for Intermediate Risk Prostate Cancer Treated with Definitive Radiotherapy: Retrospective Analysis of a National Healthcare System
Presenter: Alex Bryant, MD, MS – University of Michigan
2:30 PM – 3:45 PM ET

PSMA-PET Radiopharmaceutical Image Scoring Method (PRISM): A Practical Tool for Predicting ¹⁷⁷lu-PSMA-617 Therapy Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Hyma Polimera, MD – Penn State Cancer Institute
2:30 PM – 3:45 PM ET

Estimating Risk of Biochemical Recurrence after RT Utilizing a Convolutional Neural Network
Presenter: Martin King, MD, PhD – Brigham and Womens Hospital
2:30 PM – 3:45 PM ET

Implementation of a Patient Tracking Whiteboard for Prospective Peer Review in a Community-Based Radiation Oncology Program
Presenter: Malolan Rajagopalan, MD, MBA – Mount Carmel Health System
2:30 PM – 3:45 PM ET

Radiation Chronotherapy in Prostate Cancer: Does Time of Day of Radiation Treatment Influence Disease Outcome or Symptom Burden?
Presenter: Greeshma Rajeev-Kumar, MD – University of Chicago Medicine
2:30 PM – 3:45 PM ET

PSMA MRI Guided Prostate SBRT: Acute Toxicity and Early Results from the ARGOS-Climber Phase I/II Trial
Presenter: Sherif Ramadan, MD – Western University
2:30 PM – 3:45 PM ET

Microboost and Dosimetric Variability in Localized Prostate Cancer: Analysis of a Prospective Statewide Quality Collaborative
Presenter: Samuel Regan, MD – University of Michigan
2:30 PM – 3:45 PM ET

Metastasis-Free Survival after Adjuvant or Salvage Radiation Therapy Following Radical Prostatectomy in a National Healthcare Delivery System
Presenter: Samuel Regan, MD – University of Michigan
2:30 PM – 3:45 PM ET

Postoperative Hypofractionated Radiotherapy for Prostate Cancer: Results of a Large Cohort
Presenter: Xue-Ying Ren, MD – Peking University First Hospital
2:30 PM – 3:45 PM ET

Impact of PSMA PET-CT Findings on Dose Prescription and Target Definition in Patients with Biochemical Relapse after Radical Prostatectomy
Presenter: Christoph Resl, MD – UK Krems an der Donau
2:30 PM – 3:45 PM ET

Prostate Salvage Brachytherapy Utilization and Efficacy over Two Decades at a Single Institution
Presenter: Daniel Rosen, MD, PhD – Harvard Radiation Oncology Program
2:30 PM – 3:45 PM ET

Automated Template-Based Planning and Prostate Stereotactic Body Radiotherapy without Real-Time Seed-Tracking: A Regional Service Experience
Presenter: Amie Ross, RT – Mid North Coast Cancer Institute (MNCCI) Coffs Harbour
2:30 PM – 3:45 PM ET

Association of Absolute Amount of Pattern 4 Disease on Prostate Biopsy with Oncologic Outcomes in Intermediate-Risk Prostate Cancer: A Systematic Review
Presenter: Melissa Sam Soon, BHSc – University of Ottawa
2:30 PM – 3:45 PM ET

A Phase 2/3 Study of ¹⁷⁷Lu-TLX591 Plus SOC vs. SOC Alone in Patients with Metastatic Castration-Resistant Prostate Cancer (ProstACT GLOBAL)
Presenter: Divya Madhu, PharmD – Telix Pharmaceuticals
2:30 PM – 3:45 PM ET

Safety Profile of High-Dose Intensity Modulated Radiotherapy in Prostate Cancer: Preliminary Findings from the JROSG 17-5 Multicenter Prospective Observational Study in Japan
Presenter: Yuta Sekino, MD, PhD – University of Tsukuba
2:30 PM – 3:45 PM ET

Multi-Class Prediction Using Machine Learning to Predict Pathologic Stage in Prostate Cancer
Presenter: Hemal Semwal, MS, BS
2:30 PM – 3:45 PM ET

Hypofractionated vs. Conventionally Fractionated Radiotherapy for Prostate Cancer: A Meta-Analysis of Randomized Trials
Presenter: Parvez Shaikh, MD, ScB MScHI – West Virginia University School of Medicine
2:30 PM – 3:45 PM ET

Clinical Efficacy of Localized Salvage Prostate Cancer Retreatments Using CBCT-Guided Proton Scanning Beams with Over 2-Year Follow-Ups
Presenter: Charles Shang, MB, MS – South Florida Proton Therapy Institute
2:30 PM – 3:45 PM ET

Telemedicine Use in Older Adults with Cancer Presenting for Radiation Oncology Consultation
Presenter: Yasamin Sharifzadeh, MD – Mayo Clinic Rochester
2:30 PM – 3:45 PM ET

Patient Reported Outcomes in Radiotherapy (PRO-RT) Utilizing an Integrated Patient Portal; Results from a Prospective Single Arm Trial
Presenter: Yasamin Sharifzadeh, MD – Mayo Clinic Rochester
2:30 PM – 3:45 PM ET

Dosimetric Comparison between Adaptation Strategies for MRI-Guided Dose-Intensified Prostate Stereotactic Ablative Radiotherapy
Presenter: Julia Shi, BS – University of Texas Southwestern Medical Center
2:30 PM – 3:45 PM ET

High Risk Prostate Cancer Treated with Radiation Therapy: Favorable Outcomes in Men with PSA>20 as the Sole High Risk Factor
Presenter: Stanley Liauw, MD, FASTRO – University of Chicago
2:30 PM – 3:45 PM ET

Comparison of Urethra Morphology on CT with Urinary Catheter and MRI without Urinary Catheter after Low Dose Rate Prostate Cancer Brachytherapy
Presenter: Ingrid Sidibe, MD – CHU de Quebec - Universite Laval - Centre integre de cancerologie
2:30 PM – 3:45 PM ET

Moderately Hypofractionated Proton Therapy with or without Implantable Spacer in Patients with Localized Prostate Cancer
Presenter: Soborun Kaviraj, MD – Universitatsklinikum Dresden Klinik f Strahlentherapie und Radioonkologie
2:30 PM – 3:45 PM ET

Veterans Affairs seamless phase II/III randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for Oligometastatic pRosTate cancer (VA STARPORT)
Presenter: Abhishek Solanki, MD, MS – Loyola University Chicago Stritch School of Medicine
2:30 PM – 3:45 PM ET

Practice Patterns of Primary Stereotactic Radiotherapy for Renal Cell Carcinoma in the United States
Presenter: Yash Soni, MD, BS – UT Southwestern Medical Center
2:30 PM – 3:45 PM ET

National Use of PEG Hydrogel Spacer for Men with Prostate Cancer in the U.S. over Six Years
Presenter: Daniel Spratt, MD – University Hospitals Seidman Cancer Center
2:30 PM – 3:45 PM ET

Radiotherapy vs. Radical Prostatectomy in Patients with Intraductal Carcinoma of the Prostate
Presenter: Taylor Stamey, MOP – East Carolina University Brody School of Medicine
2:30 PM – 3:45 PM ET

Impact of Nutritional Status and Therapy on Survival among Radiotherapy Patients: A Study of a Chinese Population
Presenter: Yue Su, MD – Sichuan Cancer Hospital
2:30 PM – 3:45 PM ET

A Comprehensive Evaluation of an Independent Quality Assurance System for Intensity Modulated Proton Therapy Treatment Plans and Deliveries
Presenter: Zhong Su, PhD, MBA – University of Arkansas for Medical Sciences College of Medicine
2:30 PM – 3:45 PM ET

Implications of Rectal Wall Gel Placement in Treatment Delay
Presenter: Grace Sun, MD, BS – Michigan Medicine
2:30 PM – 3:45 PM ET

Hypoxia-Guided Dose Escalated Radiation Therapy in Prostate Cancer: A Dosimetric Feasibility Study
Presenter: Dorine de Jong, PhD – RefleXion
2:30 PM – 3:45 PM ET

Progression Free Survival Prediction for Oligometastatic Renal Cell Cancer Patients after Stereotactic Ablative Radiation Therapy
Presenter: Shanshan Tang, PhD – UT Southwestern Medical Center
2:30 PM – 3:45 PM ET

Predicting Chemoradiotherapy Induced Cardiotoxicity in Breast Cancer Patients Using Machine Learning Based Clinical, Imaging and Dosimetric Radiomics Features
Presenter: Beth Ghavidel, MS – Winship at Emory University Hospital Midtown
2:30 PM – 3:45 PM ET

Organ at Risk Dose Constraints in Conventionally Fractionated Pelvic Radiation Therapy: A Systematic Review of Clinical Trials
Presenter: Leila Tchelebi, MD – Northern Westchester Hospital
2:30 PM – 3:45 PM ET

Per-Fraction Analysis of PTV Margin Reduction and Organ Dose Optimization for Intact Prostate
Presenter: Diego Toesca, MD – Mayo Clinic Arizona
2:30 PM – 3:45 PM ET

A Phase 4 Open-Label Multicenter Study of Piflufolastat F 18 PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk Prostate Cancer: MIRROR
Presenter: Jonathan Tward, MD, PhD, FASTRO – University of Utah
2:30 PM – 3:45 PM ET

Comparison of Perirectal Spacer Placement Quality during the Learning Curve for 3 FDA Approved Products
Presenter: Jonathan Tward, MD, PhD, FASTRO – University of Utah
2:30 PM – 3:45 PM ET

Treatment Outcomes with Neoadjuvant Chemotherapy Followed by Chemoradiation for Muscle Invasive Bladder Cancer
Presenter: Melissa Usoz, MS, BS – Prisma Health Cancer Institute
2:30 PM – 3:45 PM ET

A Pilot Study of Immunological Response to PSMA-Directed Radioligand Therapy for the Treatment of Oligometastatic Prostate Cancer
Presenter: Luca Valle, MD – UCLA Radiation Oncology
2:30 PM – 3:45 PM ET

Physician Assessment and Clinical Evaluation of the Suitability of Deep Learning Based Auto Segmentation Contours for Organs at Risk Delineation in Radiation Oncology
Presenter: Sarah Way, MS – Minneapolis Radiation Oncology PA
2:30 PM – 3:45 PM ET

Assessing Bilateral Neurovascular Bundles Function with Pulsed Wave Doppler Ultrasound: Implications for Reducing Erectile Dysfunction Following Prostate Radiotherapy
Presenter: Tian Liu, PhD – Icahn School of Medicine at Mount Sinai
2:30 PM – 3:45 PM ET

Efficacy of an Adaptive Plan Quality Predictor for Decision Support in Online MR-Guided Adaptive Radiotherapy for Prostate Stereotactic Ablative Radiotherapy
Presenter: Siqiu Wang, PhD – University of Texas Southwestern Medical Center
2:30 PM – 3:45 PM ET

Daily Online Adaptive Radiotherapy for Rectal Cancer Utilizing CT-Linac: Assessing Feasibility, Toxicities and Optimal Margins
Presenter: Weiping Wang, MD, PhD – Peking Union Medical College Hospital
2:30 PM – 3:45 PM ET

Factors Associated with Completion of Treatment Course with Lutetium-177 Vipivotide Tetraxetan in Men with Metastatic Castration-Resistant Prostate Cancer at a Single Institution
Presenter: Peter Whatts, MD – Detroit Medical Center/Wayne State University
2:30 PM – 3:45 PM ET

Characterizing Failure after Trimodality Therapy in Bladder Cancer: A Retrospective Analysis of Clinical, Spatial and Dosimetric Factors
Presenter: Matthew Whitmill, MD – UNC Health
2:30 PM – 3:45 PM ET

Baseline Characteristics of Patients Enrolled on the Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL) Trial Comparing Proton Therapy vs. IMRT for Low or Intermediate R
Presenter: Jason Efstathiou, MD, PhD, FASTRO – Massachusetts General Hospital
2:30 PM – 3:45 PM ET

The Broader Impact of Specialized Outpatient Cancer Rehabilitation on Functioning and Health Outcomes during Radiation Treatment
Presenter: Kelley Wood, PhD, MS – Select Medical
2:30 PM – 3:45 PM ET

Dosimetric Study of Dose De-Escalation Using MRI-Guidance in Low and Intermediate Risk Prostate Cancer Patients with Pd-103 Low Dose Rate Brachytherapy
Presenter: Lin Wang, MS – Northwell Health
2:30 PM – 3:45 PM ET

Multivariate Analysis of Pretreatment Biomarkers Predicting Treatment Completion in Patients Undergoing Lu-177-PSMA-617 Radiopharmaceutical Therapy
Presenter: Edmond Yaghoubian, MD – UPMC
2:30 PM – 3:45 PM ET

Predictive Factors for Oliogometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Ablative Radiation (SAbR)
Presenter: Joseph Kwon, MD
2:30 PM – 3:45 PM ET

HDR Brachytherapy Boost for Unfavorable Localized Prostate Cancer: A Single Center Experience from Inception to Standard of Care
Presenter: Juanita Crook, MD – BCCancer
2:30 PM – 3:45 PM ET

Calculation of Dose Perturbations Caused by 2 mm of Intraprostatic Calcification for Permanent Prostate Seed Implant Using Pd103 in Excel/Python
Presenter: Ashraf Youssef, MD, MBA – Our Lady of Lourdes Memorial Hospital Inc.
2:30 PM – 3:45 PM ET

Caring for the Carers: Factors Associated with Perceived Burden among Caregivers of Filipino Cancer Patients Undergoing Radiation Therapy in Two Tertiary Care Hospitals in the Philippines
Presenter: Jose Ma. Zaldarriaga, MD, MBA – St. Luke's Medical Center
2:30 PM – 3:45 PM ET

Analysis of Theranostic ¹⁷⁷Lu-PSMA-617 Therapy Efficacy and Toxicity in Patients with Advanced Prostate Cancer
Presenter: Anthony Zhang, BS – UCONN Health Center
2:30 PM – 3:45 PM ET

Failure Modes and Effects Analysis Applied to Total Body Irradiation
Presenter: Hongjun Zhang, PhD – Atrium Health Levine Cancer Institute
2:30 PM – 3:45 PM ET

A Novel Six-Zone Method to Guide Delineation of Clinical Target Volume (CTV) for Postoperative Radiotherapy of Prostate Cancer, Based on the Distribution of Prostate Bed Recurrence by PSMA PET
Presenter: Simone Deng, PhD – Peking University First Hospital
2:30 PM – 3:45 PM ET

Long-Term Outcomes of SAbR for Metastatic RCC
Presenter: Lucian Zhao, MD, BS – UT Southwestern Medical Center
2:30 PM – 3:45 PM ET

Impact of CT Online Adaptive Radiotherapy on Acute Toxicity in Patients Undergoing Prostate Radiotherapy
Presenter: Lin Zhu, MD, PhD – Harvard Radiation Oncology Program
2:30 PM – 3:45 PM ET

Analysis of the Treatment Planning Quality Assurance Reports for Intensity Modulated Proton Therapy at an Established Proton Center
Presenter: Mingyao Zhu, PhD – Emory University School of Medicine
2:30 PM – 3:45 PM ET

Optimizing Rectal Dose and Minimizing Toxicity in Prostate Radiotherapy in a Randomized Pivotal Trial: Assessment of Rectal Spacer Placement Effect on Rectal Dosimetry and Toxicity
Presenter: Vishesh Agrawal, MD – Advanced Radiation Centers of New York